Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Regarding the CAD severity and angiographic characteristics, the differences between the two groups did not reach significance (p > 0.05).Baseline characteristics of the low and high sclerostin groupsCharacteristicLow scl group (n = 144)High scl group (n = 166)p valueConventional cardiovascular disease risk factorsAge, years75 (67 to 83)77 (69 to 83)0.271Male sex, %64 (44.4)72 (43.6)0.886Current smokers, %25 (17.4)39 (23.5)0.183Alcohol, %20 (13.9)29 (17.5)0.389Hypertension, %96 (66.7)101 (60.8)0.288Diabetes, %53 (36.8)57 (34.3)0.651Osteoporosis, %106 (73.6)76 (45.8)< 0.001PAD, %15 (10.4)14 (8.4)0.550History of MI, %5 (3.5)2 (1.2)0.705History of PCI, %23 (16.0)24 (14.5)0.711Systolic BP, mmHg130 (119.3 to 136.0)127 (117.8 to 136.0)0.472Diastolic BP, mmHg75 (68 to 80)72 (67 to 80)0.246BMI (kg/m2)23.0 (20.8 to 24.9)23.3 (20.8 to 25.5)0.378SCr (µmol/L)71.6 (58.7 to 89.6)72.0 (59.2 to 86.4)0.999HbA1c, %6.1 (5.7 to 6.7)6.2 (5.9 to 6.7)0.064TG, mmol/L1.2 (0.8 to 1.9)1.3 (1.0 to 1.8)0.311TC, mmol/L4.5 ± 1.14.5 ± 1.00.994LDL: C, mmol/L2.5 ± 0.92.5 ± 0.80.886HDL: C, mmol/L1.2 ± 0.31.2 ± 0.30.774CCS class1.0 (1.0 to 2.0)1.0 (1.0 to 1.0)< 0.001Frailty, %37 (25.7)54 (32.5)0.187VA, %15 (10.4)17 (10.2)0.960Bone turnover markersPTH, pg/mL32.7 (21.8 to 45.6)32.7 (20.1 to 52.7)0.828CT, pg/mL1.8 (1.2 to 2.6)1.8 (1.2 to 3.1)0.12025 (OH)D, ng/mL14.5 (9.7 to 22.5)16.7 (10.8 to 28.2)0.143BALP, µg/L10.2 (8.2 to 13.1)9.8 (8.0 to 12.3)0.320PINP, µg/L35.5 (26.4 to 46.0)36.3 (24.7 to 49.8)0.807β-CTX, µg/L0.4 (0.2 to 0.5)0.4 (0.2 to 0.5)0.369N-MID osteocalcin, µg/L16.4 (11.7 to 24.2)15.8 (11.7 to 21.2)0.192BMD (FN), g/cm30.8 (0.6 to 0.9)0.9 (0.7 to 1.0)< 0.001BMD (LS), g/cm30.9 (0.8 to 1.1)1.0 (0.9 to 1.2)0.001Angiographic characteristicsSYNTAX scores ≥ 33, %15 (10.4)13 (7.8)0.428Target vesselsLAD, %89 (61.8)102 (61.4)0.948LCX, %48 (33.3)58 (34.9)0.766RCA, %60 (41.7)66 (39.8)0.733Multivessel disease, %17 (11.8%)27 (16.3)0.262PCI failure, %4 (2.8)5 (3.0)0.902Total occlusion, %71 (49.3)85 (51.2)0.739Stent placement, %130 (90.3)152 (91.6)0.693MedicationPlatelet inhibitor, %116 (80.6)132 (79.5)0.820Beta blocker, %42 (29.2)45 (27.1)0.687Statin, %9 (6.3)2 (1.2)0.017RAS blocker, %69 (47.9)80 (48.2)0.961PAD peripheral artery disease, MI myocardial infarction, PCI percutaneous coronary intervention, BP blood pressure, BMI body mass index, SCr serum creatine, HbA1c glycated hemoglobin, TG triglycerides, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, CCS Canadian Cardiovascular Society, VA: vigorous activity, CT calcitonin, 25(OH)D 25-hydroxyvitamin D, BALP bone alkaline phosphatase, PINP propeptide of type I procollagen, β-CTX C-terminal cross-linked telopeptide, N-MID osteocalcin N-terminal midfragment of osteocalcin, BMD bone mineral density, FN femoral neck, LS lumber spine, LAD left anterior descending artery, LCX left circumflex branch coronary artery, RCA right coronary artery
Source: Baseline characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Participants were stratified into 2 groups according to the median value of serum sclerostin levels: those with low serum sclerostin levels (the low scl group) and those with high sclerostin levels (the high scl group).
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Serum sclerostin and adverse outcomes in elderly patients with stable coronary artery disease undergoing percutaneous coronary intervention
Study design awaiting verification · Aging Clinical and Experimental Research · 2019
Original publication title
Serum sclerostin and adverse outcomes in elderly patients with stable coronary artery disease undergoing percutaneous coronary intervention
© The Author(s) 2019
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Recently, sclerostin, a bone-derived protein, has been shown to play a key role in atherosclerosis progression. However, few studies have investigated the influence of sclerostin on cardiovascular disease prognosis. We investigated the relationship between serum sclerostin levels and adverse outcomes in elderly patients with stable coronary artery disease (SCAD) who were undergoing percutaneous coronary intervention (PCI).
Source: BackgroundAbstract: What methods does the paper describe?
We enrolled 310 elderly SCAD patients who underwent PCI in this study and followed them 3 years. According to the median serum sclerostin levels, subjects were stratified into a low sclerostin (low scl) group (n = 144) and a high sclerostin (high scl) group (n = 166). Time-to-event analyses were performed with the Kaplan: Meier method. Associations between sclerostin levels and main adverse cardiovascular and cerebrovascular events (MACCEs) and mortality were evaluated by Cox multivariate regression analysis. The prognostic power of predictive models was verified by the concordance index and receiver operating characteristic curve analysis.
Source: MethodsAbstract: Electronic supplementary material
The online version of this article (10.1007/s40520-019-01393-2) contains supplementary material, which is available to authorized users.
Source: Electronic supplementary materialAbstract: Results
The high scl group had a significantly higher MACCE-free rate and better survival than the low scl group. Serum sclerostin was an independent predictor and could improve the prognostic power for adverse outcomes. In addition, serum sclerostin levels were significantly associated with bone turnover markers, a lower presence of multivessel disease and a lower CCS angina class.
Source: ResultsAbstract: Conclusions
Serum sclerostin is a prognostic parameter for predicting and intervening in the adverse outcomes of elderly SCAD patients undergoing PCI, which may be explained by its potential role in the bone: vascular axis.
Source: ConclusionsAuthors’ abstract
Background
Recently, sclerostin, a bone-derived protein, has been shown to play a key role in atherosclerosis progression. However, few studies have investigated the influence of sclerostin on cardiovascular disease prognosis. We investigated the relationship between serum sclerostin levels and adverse outcomes in elderly patients with stable coronary artery disease (SCAD) who were undergoing percutaneous coronary intervention (PCI).
Methods
We enrolled 310 elderly SCAD patients who underwent PCI in this study and followed them 3 years. According to the median serum sclerostin levels, subjects were stratified into a low sclerostin (low scl) group (n = 144) and a high sclerostin (high scl) group (n = 166). Time-to-event analyses were performed with the Kaplan: Meier method. Associations between sclerostin levels and main adverse cardiovascular and cerebrovascular events (MACCEs) and mortality were evaluated by Cox multivariate regression analysis. The prognostic power of predictive models was verified by the concordance index and receiver operating characteristic curve analysis.
Results
The high scl group had a significantly higher MACCE-free rate and better survival than the low scl group. Serum sclerostin was an independent predictor and could improve the prognostic power for adverse outcomes. In addition, serum sclerostin levels were significantly associated with bone turnover markers, a lower presence of multivessel disease and a lower CCS angina class.
Conclusions
Serum sclerostin is a prognostic parameter for predicting and intervening in the adverse outcomes of elderly SCAD patients undergoing PCI, which may be explained by its potential role in the bone: vascular axis.
Electronic supplementary material
The online version of this article (10.1007/s40520-019-01393-2) contains supplementary material, which is available to authorized users.
Publication and source details
Original title: Serum sclerostin and adverse outcomes in elderly patients with stable coronary artery disease undergoing percutaneous coronary intervention
Wuyang He; Chunqiu Li; Qingwei Chen; Tingting Xiang; Peng Wang; Jun Pang
Aging Clinical and Experimental Research · 2019
© The Author(s) 2019https://creativecommons.org/licenses/by/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.http://dx.doi.org/10.13039/501100001809National Natural Science Foundation of China31871182Chen Qingwei Technology Project Affiliated to the Science Department of Yuzhong District of Chongqing city20170406Chen Qingwei Scientific Research Projects of Chongqing Sports BureauB201812Chen Qingwei the Project of Chongqing Municipal Health Planning Commission2017MSXM038He Wuyang Basic and Frontier Research Program of Chongqing Science and Technology Commissiocstc2015jcyjA10074Chen Qingwei Major Project of Community Education and Scientific Research of Chongqing Education CommissioSJ2018-001Chen QingweiRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T18:17:47.433280+00:00
DOI: 10.1007/s40520-019-01393-2 · PMC7532957